Pediatric Drugs

, Volume 15, Issue 1, pp 59–70 | Cite as

DTaP-IPV-Hep B-Hib Vaccine (Hexaxim®)

A Review of its Use in Primary and Booster Vaccination
Adis Drug Evaluation


Hexaxim® (DTaP-IPV-Hep B-Hib) is a new, thiomersal-free, fully liquid, hexavalent combination pediatric vaccine containing diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, recombinant hepatitis B virus surface antigen produced in the yeast Hansenula polymorpha, and Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid. It is currently registered in markets outside of the EU for primary vaccination of infants from 6 weeks of age and for booster vaccination up to 24 months of age. In randomized controlled trials, primary vaccination of infants with Hexaxim® using various immunization schedules was highly immunogenic for all vaccine component antigens regardless of the administration schedule, producing high levels of seroprotection or seroconversion for each antigen. Hexaxim® was as immunogenic as the comparator DTwP- or DTaP-based vaccines in these studies. The serological responses were generally sustained at high levels over a follow-up of ≈1 year, and booster vaccination at 15–18 months further enhanced the immune response. Hexaxim® was less reactogenic than a DTwP-based combination vaccine, and displayed a tolerability profile similar to those of the comparator DTaP-based combination vaccines. Thus, Hexaxim® provides effective seroprotection or seroconversion against six major childhood diseases simultaneously, both as primary and booster vaccination, and offers the benefits and convenience of a fully liquid, ready-to-use vaccine


  1. 1.
    World Health Organization. WHO recommendations for routine immunization - summary tables. 2012. Accessed 27 Nov 2012.
  2. 2.
    Skibinski DAG, Baudner BC, Singh M, et al. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72.PubMedCrossRefGoogle Scholar
  3. 3.
    World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385–400.Google Scholar
  4. 4.
    Kitchin NRE. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Expert Rev Vaccines. 2011;10(5):605–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Madhi SA, Mitha I, Cutland C, et al. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J. 2011;30(4):e68–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96.PubMedGoogle Scholar
  7. 7.
    Plotkin SA, Liese J, Madhi SA, et al. A DTaP-IPV//PRP-T vaccine (Pentaxim™): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011;10(7):981–1005.PubMedCrossRefGoogle Scholar
  8. 8.
    Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccin. 2008;4(5):328–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years. Vaccine. 2010;28(20):3595–601.PubMedCrossRefGoogle Scholar
  10. 10.
    European Medicines Agency. European Medicines Agency recommends suspension of Hexavac. 2005. Accessed 27 Nov 2012.
  11. 11.
    European Medicines Agency. Scientific conclusions and grounds for the suspension of the marketing authorisation of Hexavac presented by the EMEA. Accessed 22 Nov 2012.
  12. 12.
    Jorgensen P, Poethko-Muller C, Hellenbrand W, et al. Low hepatitis B immunogenicity of a hexavalent vaccine widely used in Germany: results of the German Health Survey for Children and Adolescents, 2003–2006. Epidemiol Infect. 2010;138(11):1621–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Zanetti AR, Romano L, Giambi C, et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis. 2010;10(11):755–61.PubMedCrossRefGoogle Scholar
  14. 14.
    European Medicines Agency. Hexaxim: summary of opinion. 2012. Accessed 27 Nov 2012.
  15. 15.
    Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15–18 months compared to licensed vaccines in Turkish infants [abstract plus poster]. Presented at 5th Asian Congress of Pediatric Infectious Diseases, 23–26 Sep 2010, Taipei.Google Scholar
  16. 16.
    Lanata C, Zambrano B, Ecker L, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2–4–6 months of age in Peru. J Vaccines Vaccin. 2012;3(1):1000128.CrossRefGoogle Scholar
  17. 17.
    Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez P, Arguedas A, Consuelo-Miranda M, et al. Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America. Presented at 15th International Congress on Infectious Diseases, 13–16 Jun 2012, Bangkok.Google Scholar
  19. 19.
    Macias M, Lanata CF, Zambrano B, et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatr Infect Dis J. 2012;31(8):e126–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Becerra Aquino AG, Gutierrez Brito M, Aranza Doniz CE, et al. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine. 2012;30(45):6492–500.CrossRefGoogle Scholar
  21. 21.
    Madhi SA, Mitha I, Koen A, et al. Post-primary antibody persistence and immunogenicity/safety of an investigational DTaP-IPV-Hep B-PRP-T (Hexaxim™) booster vaccine compared to licensed vaccines in South Africa [abstract plus poster]. Presented at 7th Congress of the World Society for Pediatric Infectious Diseases, 16–19 Nov 2011, Melbourne.Google Scholar
  22. 22.
    Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):e24–30.PubMedCrossRefGoogle Scholar
  23. 23.
    World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84(40):405–19.Google Scholar
  24. 24.
    Floreani A, Baldo V, Cristofoletti M, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine. 2004;22(5–6):607–10.PubMedGoogle Scholar
  25. 25.
    Santos-Lima E, B’Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) following primary series administration at 2, 4, 6 months of age in Latin America. Vaccine. doi:10.1016/j.vaccine.2012.11.087
  26. 26.
    UNICEF. Immunization: why are children dying? 2012. Accessed 28 Nov 2012.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations